Ligand to Participate in November Investor Conferences

Core Insights - Ligand Pharmaceuticals is actively engaging with investors through upcoming conferences, indicating a focus on investor relations and potential growth opportunities [1][4] Company Overview - Ligand Pharmaceuticals is a biopharmaceutical company that supports the clinical development of high-value medicines through financing and licensing technologies [2] - The company's business model aims to create a diversified portfolio of biotech and pharmaceutical product revenue streams while maintaining a low corporate cost structure [2] - Ligand partners with leading pharmaceutical companies to leverage their expertise in late-stage development, regulatory management, and commercialization [2] Technology Platforms - Ligand operates two royalty-generating technology platforms: Captisol® and NITRICIL™ - Captisol® is designed to optimize the solubility and stability of drugs [2] - NITRICIL™ allows for tunable dosing and adjustable drug release profiles for various indications [2] Upcoming Events - Management will participate in the UBS Global Healthcare Conference on November 10, 2025, for one-on-one meetings [4] - A fireside chat is scheduled for November 12, 2025, at the Stifel 2025 Healthcare Conference [4] - Ligand will present at the Southwest IDEAS 2025 Investor Conference on November 20, 2025 [4]